On May 19, 2022 EpiAxis Therapeutics reported to attend and present at the 16th Bioshares Biotech Summit this month in Albury, NSW (Press release, EpiAxis Therapeutics, MAY 19, 2022, View Source;utm_medium=rss&utm_campaign=epiaxis-therapeutics-presents-bioshares-biotech-summit [SID1234614860]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioShares is a life science conference mainly targeting ASX-listed Australian biotech companies, biotech investors, fund managers and brokers and entrepreneurs. The conference was organised by Bioshares, Australia’s leading independent biotech investment publication.

The event featured an intense two-day program, with approximately 25 speakers and excellent networking opportunities within the biotech industry and investment sectors. It was a valuable opportunity to access to investors who support the Australian life science sector.

EpiAxis was represented at Bioshares by Chairman Dr David Fuller, Director Rob McInnes and CEO Dr Jeremy Chrisp. Dr Chrisp gave a presentation during the "New Kids on the Block" session on day two of the conference.

Dr Fuller said: "It was great to see Bioshares return and be face-to-face with industry colleagues and friends again after the COVID-19 pandemic. The EpiAxis presentation was well received and marked the start of our next fundraising effort, with discussions held with many of the investors and funds present."